Onze Lieve Vrouwe Gasthuis is a major clinical hospital situated near Oosterpark in Amsterdam in the Netherlands. Founded in 1898, it is now part of OLVG, a network of hospitals formed by the merger of the Onze Lieve Vrouwe Gasthuis with the former Sint Lucas Andreas hospital, and is now known as OLVG, West Location.

During the past decade, Onze Lieve Vrouwe Gasthuis conducted 132 clinical trials. In the 10-year time frame, 132 clinical trials started and 23 clinical trials were completed, i.e. on average, 17.4% percent of trials that started reached the finish line to date. In the past 5 years, 53 clinical trials started and 14 clinical trials were completed. i.e. 26.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Onze Lieve Vrouwe Gasthuis" #1 sponsor was "European Organisation for Research and Treatment of Cancer - EORTC" with 28 trials, followed by "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 23 trials sponsored, "Onze Lieve Vrouwe Gasthuis" with 12 trials sponsored, "Radboud University Medical Center" with 11 trials sponsored and "Erasmus Medical Center" with 11 trials sponsored. Other sponsors include 169 different institutions and companies that sponsored additional 105 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Onze Lieve Vrouwe Gasthuis" #1 collaborator was "ZonMw: The Netherlands Organisation for Health Research and Development" with 20 trials as a collaborator, "Onze Lieve Vrouwe Gasthuis" with 9 trials as a collaborator, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 6 trials as a collaborator, "Dutch Cancer Society" with 6 trials as a collaborator and "Erasmus Medical Center" with 6 trials as a collaborator. Other collaborators include 318 different institutions and companies that were collaborators in the rest 232 trials.

According to Clinical.Site data, the most researched conditions in "Onze Lieve Vrouwe Gasthuis" are "Coronary Artery Disease" (15 trials), "Breast Cancer" (12 trials), "Leukemia" (8 trials), "Atrial Fibrillation" (7 trials) and "Lymphoma" (7 trials). Many other conditions were trialed in "Onze Lieve Vrouwe Gasthuis" in a lesser frequency.

Most popular intervention types in "Onze Lieve Vrouwe Gasthuis" are "Drug" (121 trials), "Device" (55 trials), "Procedure" (55 trials), "Other" (36 trials) and "Biological" (16 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "cyclophosphamide" (10 trials), "radiation therapy" (9 trials), "cisplatin" (8 trials) and "doxorubicin hydrochloride" (7 trials). Other intervention names were less common.

The vast majority of trials in "Onze Lieve Vrouwe Gasthuis" are 233 trials for "All" genders, 22 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are 74 active trials in "Onze Lieve Vrouwe Gasthuis". 2 are not yet recruiting, 35 are recruiting, 33 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 127 completed trials in Onze Lieve Vrouwe Gasthuis, 1 suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in Onze Lieve Vrouwe Gasthuis, 0 "Phase 1" clinical trials were conducted, 33 "Phase 2" clinical trials and 77 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 33 trials, and there were also 79 trials that are defined as “Not Applicable".